Comparing Common Safety Outcomes in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Various First-line Platinum-containing Chemotherapy Combination Regimens (H3E-MC-B026)

Study identification

• EU PAS number:
  EUPAS10688
• Study ID:
  27984
• Official title and acronym:
  Comparing Common Safety Outcomes in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Various First-line Platinum-containing Chemotherapy Combination Regimens (H3E-MC-B026)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Finalised

Research institutions and networks

Institutions

Eli Lilly and Company

Study timelines

Date when funding contract was signed

Planned: 05/02/2015

Actual: 05/02/2015

Study start date

Planned: 15/01/2016

Actual: 15/01/2016

Date of final study report

Planned: 31/05/2016

Actual: 01/03/2018

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable